Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes

Journal of Neuroscience Research

Volumn 84, Issue 3, 2006, Pages 675-682

  Moran Gates, Taylor ^a   Massari, Carla ^a   Graulich, Atnaury ^b   Liégeois, Jean François ^b   Tarazi, Frank I ^a,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MCLEAN HOSPITAL   (United States)

Author keywords

Antipsychotic drugs; Autoradiography; Caudate putamen; Dopamine receptors; Frontal cortex; JL 13; Serotonin receptors

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; FLUPHENAZINE; JL 13; OLANZAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG EFFECT; FRONTAL CORTEX; HIPPOCAMPUS; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PUTAMEN; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; CLOZAPINE; DOPAMINE; DOWN-REGULATION; MENTAL DISORDERS; OXAZEPINES; PIPERAZINES; PROSENCEPHALON; PYRIDINES; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; SEROTONIN; SYNAPTIC TRANSMISSION; TIME; UP-REGULATION;

EID: 33746878519     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.20972     Document Type: Article

References (33)

1. 3 dopamine receptor. J Recept Signal Transduct 24:117-130.
2. Arnt J, Skarsfeldt T. 1998. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.
3. Baldessarini RJ, Frankenburg FR. 1991. Clozapine. A novel antipsychotic agent. N Engl J Med 324:746-754.
4. Baldessarini RJ, Tarazi FI. 2005. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill. p 461-500.
5. 2 receptors mediate dopamine Dj-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats. Synapse 50:164-170.
6. 1 agonist SKF 82958. Neuropharmacology 49:350-358.
7. Bruhwyler J, Liégeois J-F, Bergman J, Carey G, Goudie A, Taylor A, Meltzer H, Delarge J, Géczy J. 1997. JL 13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioral properties. Pharmacol Res 36:255-264.
8. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. 1995. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13:177-213.
9. Casey DE, Bruhwyler J, Delarge J, Géczy J, Liégeois J-F. 2001. The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates. Psychopharmacology 157:228-235.
10. 4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Biol Psychiatry 55:445-451.
11. Ellenbroek BA, Liégeois J-F. 2003. JL 13, an atypical antipsychotic: a preclinical review. CNS Drug Rev 9:41-56.
12. Ellenbroek BA, Liégeois J-F, Bruhwyler J, Cools AR. 2001. Effects of JL 13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. J Pharmacol Exp Ther 298:386-391.
13. Fischer V, Haar JA, Greiner L, Lloyd RV, Mason RP. 1991. Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis. Mol Pharmacol 40:846-853.
14. Florijn WJ, Tarazi FI, Creese I. 1997. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 280:561-569.
15. 4 receptor knockout mice. J Mol Neurosci 22:167-178.
16. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531.
17. Invernizzi R, Garavaglia C, Samanin R. 2000. JL 13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity, increases extracellular dopamine in the prefrontal cortex, but not in the striatum and the nucleus accumbens of rats. Naunyn Schmiedeberg's Arch Pharmacol 361:298-302.
18. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 54:567-572.
19. 1 hippocampus. Biol Psychiatry 31:560-570.
20. 2-dopamine receptors in the primate cerebral cortex. Proc Natl Acad Sci U S A 91:4353-4356.
21. Liégeois J-F, Mouithys-Mickalad A, Bruhwyler J, Delarge J, Petit C, Kauffmann JM, Lamy M. 1997. JL 13, a potential successor to clozapine, is less sensitive to oxidative phenomena. Biochem Biophys Res Commun 238:252-255.
22. Meltzer HY. 1999. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21:106S-115S.
23. 2 pKi vales. J Pharmacol Exp Ther 251:238-246.
24. 4 receptor subtypes differentially modulate recurrent excitatory synapses in prefrontal cortical pyramidal neurons. Neuropsychopharmacology 31:318-338.
25. 1-like interactions. Synapse 59:107-118.
26. 4-like dopamine receptors. Neuropsychopharmacology 17:186-196.
27. 4-like dopamine receptors: common targets for typical, atypical and experimental antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 22:693-707.
28. Tarazi FI, Zhang K, Baldessarini RJ. 2001. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 297:711-717.
29. Tarazi FI, Zhang K, Baldessarini RJ. 2002. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology 161:263-270.
30. 4 receptors: beyond schizophrenia. J Recept Signal Transduct Res 24:131-147.
31. Waddington JL, Casey D. 2000. Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Waddington JL, Buckley PF, editors. Schizophrenia and mood disorders. Oxford: Butterworth-Heinemann. p 1-13.
32. Zhang K, Weiss NT, Tarazi FI, Kula NS, Baldessarini RJ. 1999. Effects of alkylating agents on dopamine D3 receptors: selective protection by dopamine. Brain Res 847:32-37.
33. 4 receptor in rats. Neuropsychopharmacology 29:1648-1655.